Key result
The MultiLink stent demonstrated less leukocyte adhesion compared to the Palmaz Schatz stent in an in vitro circulation model.
Why the study?
Does the MultiLink stent reduce platelet and leukocyte adhesion compared to the Palmaz Schatz stent in an in vitro model?
Does the MultiLink stent reduce platelet and leukocyte adhesion compared to the Palmaz Schatz stent in an in vitro model?
The MultiLink stent demonstrates improved hemocompatibility with reduced leukocyte adhesion and better response to antiplatelet treatment compared to the Palmaz Schatz stent in an in vitro model.
Answers are grounded in this paper and cite their sources.
Supports further preclinical hemocompatibility testing of MultiLink stents; leaves open translation to clinical thrombosis reduction.
BACKGROUND: Platelet and leukocyte deposition onto metallic struts can be a crucial factor in the outcome of a coronary stenting procedure. By means of an in vitro, closed-loop circulation model, we aimed to assess blood-stent interaction patterns for a new stainless steel stent (MultiLink, Guidant Nederland BV, Nieuwegein, the Netherlands). METHODS: The effect of MultiLink (n=20) on blood cells and blood activation was studied by biochemical assays. Platelet and leukocyte adhesion to MultiLink were studied by immunofluorocytometric assays (anti-GpIIIa [CD 61] and anti-CD11b labeled antibodies, respectively), and by scanning electron microscopy. MultiLink was compared with empty circuits (n=20) and to the Palmaz Schatz stent (n=20). Experiments were performed both in the presence and in the absence of an antiplatelet agent (15 microg/mL of indomethacin). RESULTS: No significant effect on blood cells and blood activation was demonstrated for MultiLink. Antiplatelet treatment significantly reduced platelet adhesion to MultiLink (from 3.78+/-1.28 to 2.23+/-0.57 x 10(6) count per second [cps]/stent) but not to the Palmaz Schatz stent (from 4.11+/-0.31 to 5.02+/-1.29 x 10(6) cps/stent)(P=0.011). Leukocyte adhesion to MultiLink was significantly less than adhesion to the Palmaz Schatz stent (7.95+/-1.59 vs. 9.16+/-1.36 x 10(6) cps/stent, respectively; P=0.016), regardless of the presence of antiplatelet treatment. CONCLUSIONS: When compared with a traditional stainless steel stent, MultiLink seems to have features of improved hemocompatibility, and single antiplatelet treatment is proposed as the treatment of choice to prevent platelet deposition.
No takes yet. Share an insight, caveat, or question.
Amoroso et al. (2001) studied Coronary stenting (in vitro) (n=60). MultiLink stent vs. Palmaz Schatz stent and empty circuits was evaluated on Leukocyte adhesion (x 10^6 cps/stent) (p=0.016). The MultiLink stent demonstrated less leukocyte adhesion compared to the Palmaz Schatz stent in an in vitro circulation model.
Synapse has enriched 10 related papers. Consider them for comparative context: